helmholtzeyeinstituteРоссийский офтальмологический журналRussian Ophthalmological Journal2072-00762587-5760Real time Publishers10.21516/2072-0076-2023-16-2-153-159helmholtzeyeinstitute-1251Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWSНеоваскуляризация роговицы: современный взгляд на молекулярные механизмы и методы терапииCorneal neovascularization: a modern view of molecular mechanisms and methods of therapyhttps://orcid.org/0000-0001-9080-3170АржиматоваГ. Ш.ArzhimatovaG. S.

Гульжиян Шевкетовна Аржиматова, канд. мед. наук, доцент кафедры офтальмологии, ул. Баррикадная, д. 2/1, стр. 1, Москва, 125993;

руководитель офтальмологического центра, 2-й Боткинский пр-д, д. 5, Москва, 125284

Gulzhiyan Sh. Arzhimatova, Cand. of Med. Sci., associate professor, 2/1, Bldg. 1, Barricadnaya St., Moscow, 125993;

head, 5, 2nd Botkinsky Drive, Moscow, 125284

https://orcid.org/0000-0002-7101-5782СалиховЭ. А.SalikhovE. A.

Эльдар Амирович Салихов, канд. мед. наук, заведующий офтальмологическим  отделением № 602, 2-й Боткинский пр-д, д. 5, Москва, 125284

Eldar A. Salikhov, Cand. of Med. Sci., head of ophthalmology department No. 602,

5, 2nd Botkinsky Drive, Moscow, 125284

https://orcid.org/0000-0003-1537-1405ШемякинМ. Ю.ShemyakinM. Y.

Матвей Юрьевич Шемякин, врач-офтальмолог офтальмологического отделения № 64 МГОЦ, 2-й Боткинский пр-д, д. 5, Москва, 125284

Matvey Yu. Shemyakin, ophthalmologist of the ophthalmological department No. 64,

5, 2nd Botkinsky Drive, Moscow, 125284

matvei.shemyakin@gmail.comФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России; Московский городской офтальмологический центр (МГОЦ) ГБУЗ «Городская клиническая больница им. С.П. Боткина» департамента здравоохранения МосквыРоссияRussian Medical Academy of Continuing Professional Education; Moscow City Ophthalmological Center, S.P. Botkin HospitalRussian FederationМосковский городской офтальмологический центр (МГОЦ) ГБУЗ «Городская клиническая больница им. С.П. Боткина» департамента здравоохранения МосквыРоссияMoscow City Ophthalmological Center, S.P. Botkin HospitalRussian Federation202302072023162153159Copyright © Аржиматова Г.Ш., Салихов Э.А., Шемякин М.Ю., 20232023Аржиматова Г.Ш., Салихов Э.А., Шемякин М.Ю.Arzhimatova G.S., Salikhov E.A., Shemyakin M.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://roj.igb.ru/jour/article/view/1251

В обзоре литературы подробно освещены вопросы этиологии, патогенеза и молекулярных механизмов неоваскуляризации роговицы. Описаны сигнальные молекулы, участвующие в процессе неоваскулогенеза, а также их антагонисты — антиангиогенные факторы. На основе клинических исследований описана роль сигнальных белков — фактора роста эндотелия сосудов (VEGF), матричных металлопротеиназ и их рецепторов в качестве современных мишеней терапии. Представлены возможности генной и биоинженерной терапии — перспективных методов лечения неоваскуляризации роговицы. 

This review provides a detailed summary of the issues of etiology, pathogenesis and molecular mechanisms of corneal neovascularization. Signaling molecules involved in the process of neovasculogenesis, as well as their antagonists, antiangiogenic factors, are described. The role of signaling proteins VEGF, MMP and their receptors as modern targets of therapy is described on the basis of a series of clinical studies. The potentials of gene and bioengineering therapy as a promising method of treating corneal neovascularization are presented.

терапия неоваскуляризации роговицыпроангиогенные факторыантиангиогенные факторыантиVEGF терапиягенные пути неоваскулогенеза роговицыcorneal neovascularization therapypro-angiogenic factorsanti-angiogenic factorsanti-VEGF therapygene pathways for corneal neovasculogenesisReferencesLee P, Wang CC, Adamis AP. Ocular Neovascularization. Survey of Ophthalmology. 1998; 43 (3): 245–69. doi: 10.1016/s0039-6257(98)00035-6Lee P, Wang CC, Adamis AP. Ocular Neovascularization. Survey of Ophthalmology. 1998; 43 (3): 245–69. doi: 10.1016/s0039-6257(98)00035-6Gonz lez-Andrades M,. Garz n I, Gasc n MI, et al. Sequential development of intercellular junctions in bioengineered human corneas. J Tissue Eng Regen Med. 2009; (3): 442–9. doi: 10.1002/term.178Gonz lez-Andrades M,. Garz n I, Gasc n MI, et al. Sequential development of intercellular junctions in bioengineered human corneas. J Tissue Eng Regen Med. 2009; (3): 442–9. doi: 10.1002/term.178Qazi Y, Wong G, Monson B, Stringham J, Ambati BK. Corneal transparency: Genesis, maintenance and dysfunction. Brain Research Bulletin. 2010; 81 (2–3): 198–210. doi: 10.1016/j.brainresbull.2009.05.019Qazi Y, Wong G, Monson B, Stringham J, Ambati BK. Corneal transparency: Genesis, maintenance and dysfunction. Brain Research Bulletin. 2010; 81 (2–3): 198–210. doi: 10.1016/j.brainresbull.2009.05.019Oldman JN, Benedek GB. The relationship between morphology and transparency in the non-swelling corneal stroma of the shark. Invest Ophthalmology. 1967; 6 (6): 574–600.Oldman JN, Benedek GB. The relationship between morphology and transparency in the non-swelling corneal stroma of the shark. Invest Ophthalmology. 1967; 6 (6): 574–600.Lim JJ. Na+ transport across the rabbit corneal epithelium. Curr Eye Res. 1981; 1 (4): 255–8. doi: 10.3109/02713688109001856Lim JJ. Na+ transport across the rabbit corneal epithelium. Curr Eye Res. 1981; 1 (4): 255–8. doi: 10.3109/02713688109001856Lim JJ, Ussing HH. Analysis of presteady-state Na+ fluxes across the rabbit corneal endothelium. J Membrane Biol. 1982; (65): 197–204. https://doi.org/10.1007/bf01869963Lim JJ, Ussing HH. Analysis of presteady-state Na+ fluxes across the rabbit corneal endothelium. J Membrane Biol. 1982; (65): 197–204. https://doi.org/10.1007/bf01869963Stiemke MM, Edelhauser HF, Geroski DH. The developing corneal endothelium: correlation of morphology, hydration, and Na/K ATPase pump site density. Curr Eye Res. 1991; 10 (2): 145–56. https://doi.org/10.3109/02713689109001742Stiemke MM, Edelhauser HF, Geroski DH. The developing corneal endothelium: correlation of morphology, hydration, and Na/K ATPase pump site density. Curr Eye Res. 1991; 10 (2): 145–56. https://doi.org/10.3109/02713689109001742Edelhauser HF. Castroviejo lecture: the resiliency of the corneal endothelium to refractive and intraocular surgery. Cornea. 2000; 19 (3): 263–73. https://doi.org/10.1097/00003226-200005000-00002Edelhauser HF. Castroviejo lecture: the resiliency of the corneal endothelium to refractive and intraocular surgery. Cornea. 2000; 19 (3): 263–73. https://doi.org/10.1097/00003226-200005000-00002Armitage WJ, Dick AD, Bourne WM. Predicting endothelial cell loss and long-term corneal graft survival. Invest Ophthalmol Vis Sci. 2003; 44 (3): 326–31 https://doi.org/10.1167/iovs.02-1255Armitage WJ, Dick AD, Bourne WM. Predicting endothelial cell loss and long-term corneal graft survival. Invest Ophthalmol Vis Sci. 2003; 44 (3): 326–31 https://doi.org/10.1167/iovs.02-1255Matsuda M, Yee RW, Edelhauser HF. Comparison of the corneal endothelium in an American and a Japanese population. Arch Ophthalmology. 1985; 103 (1): 68–70. https://doi.org/10.1001/archopht.1985.0105000072023Matsuda M, Yee RW, Edelhauser HF. Comparison of the corneal endothelium in an American and a Japanese population. Arch Ophthalmology. 1985; 103 (1): 68–70. https://doi.org/10.1001/archopht.1985.0105000072023Kvanta A. Ocular angiogenesis: the role of growth factors. Acta Ophthalmol Scand. 2006; 84 (3): 282–8. https://doi.org/10.1111/j.1600-0420.2006.00659.xKvanta A. Ocular angiogenesis: the role of growth factors. Acta Ophthalmol Scand. 2006; 84 (3): 282–8. https://doi.org/10.1111/j.1600-0420.2006.00659.xBurger PC, Chandler DB, Klintworth GK. Corneal neovascularization as studied by scanning electron microscopy of vascular casts. Lab Invest. 1983; 48 (2): 169–80.Burger PC, Chandler DB, Klintworth GK. Corneal neovascularization as studied by scanning electron microscopy of vascular casts. Lab Invest. 1983; 48 (2): 169–80.Zhang S X, Ma J. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res. 2007; 26 (1): 1–37. doi: 10.1016/j.preteyeres.2006.09.002Zhang S X, Ma J. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res. 2007; 26 (1): 1–37. doi: 10.1016/j.preteyeres.2006.09.002Menzel-Severing J Emerging techniques to treat corneal neovascularisation. Eye. 2011; 26 (1): 2-12. doi: 10.1038/eye.2011.246Menzel-Severing J Emerging techniques to treat corneal neovascularisation. Eye. 2011; 26 (1): 2-12. doi: 10.1038/eye.2011.246Liesegang TJ. Physiologic changes of the cornea with contact lens wear. CLAO J. 2002; 28 (1): 12-27. PMID: 11838985.Liesegang TJ. Physiologic changes of the cornea with contact lens wear. CLAO J. 2002; 28 (1): 12-27. PMID: 11838985.Wuest T, Zheng M, Efstathiou S, et al. The herpes simplex virus-1 transactivator infected cell protein-4 drives VEGF-A dependent neovascularization. PLoS Pathog. 2011; 7 (10): e1002278. https://doi.org/10.1371/journal.ppat.1002278Wuest T, Zheng M, Efstathiou S, et al. The herpes simplex virus-1 transactivator infected cell protein-4 drives VEGF-A dependent neovascularization. PLoS Pathog. 2011; 7 (10): e1002278. https://doi.org/10.1371/journal.ppat.1002278Zheng M, Deshpande S, Lee S, Ferrara N, Rouse BT. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol. 2001; 75 (20): 9828–35. 2001. https://doi.org/10.1128/JVI.75.20.9828-9835.2001Zheng M, Deshpande S, Lee S, Ferrara N, Rouse BT. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol. 2001; 75 (20): 9828–35. 2001. https://doi.org/10.1128/JVI.75.20.9828-9835.2001Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000; 41 (9): 2514–22.Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000; 41 (9): 2514–22.Penn JS, Madan A, Caldwell RB, et al. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008; 27 (4): 331–71. https://doi.org/10.1016/j.preteyeres.2008.05.001Penn JS, Madan A, Caldwell RB, et al. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008; 27 (4): 331–71. https://doi.org/10.1016/j.preteyeres.2008.05.001Chung ES, Chauhan SK, Jin Y, et al. Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands. Am J Pathol. 2009; 175 (5): 1984–92. https://doi.org/10.2353/ajpath.2009.080515Chung ES, Chauhan SK, Jin Y, et al. Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands. Am J Pathol. 2009; 175 (5): 1984–92. https://doi.org/10.2353/ajpath.2009.080515Clements JL, Dana R. Inflammatory corneal neovascularization: etiopathogenesis. Semin Ophthalmol. 2011; 26 (4–5): 235–45. doi: 10.3109/08820538.2011.588652Clements JL, Dana R. Inflammatory corneal neovascularization: etiopathogenesis. Semin Ophthalmol. 2011; 26 (4–5): 235–45. doi: 10.3109/08820538.2011.588652Itoh N, Ornitz DM. Evolution of the FGF and FGFR gene families. Trends Genet. 2004; 20 (11): 563–9. https://doi.org/10.1016/j.tig.2004.08.007Itoh N, Ornitz DM. Evolution of the FGF and FGFR gene families. Trends Genet. 2004; 20 (11): 563–9. https://doi.org/10.1016/j.tig.2004.08.007Xuan M, Wang S, Liu X, et al. Proteins of the corneal stroma: importance in visual function. Cell Tissue Res. 2016; 364 (1): 9–16. https://doi.org/10.1007/s00441-016-2372-3Xuan M, Wang S, Liu X, et al. Proteins of the corneal stroma: importance in visual function. Cell Tissue Res. 2016; 364 (1): 9–16. https://doi.org/10.1007/s00441-016-2372-3Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci. 2017; 147: 1–73. https://doi.org/10.1016/bs.pmbts.2017.02.005Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci. 2017; 147: 1–73. https://doi.org/10.1016/bs.pmbts.2017.02.005Shi W, Liu J, Li M, Gao H, Wang T. Expression of MMP, HPSE, and FAP in stroma promoted corneal neovascularization induced by different etiological factors. Curr Eye Res. 2010; 35 (11): 967–77. https://doi.org/10.3109/02713683.2010.502294Shi W, Liu J, Li M, Gao H, Wang T. Expression of MMP, HPSE, and FAP in stroma promoted corneal neovascularization induced by different etiological factors. Curr Eye Res. 2010; 35 (11): 967–77. https://doi.org/10.3109/02713683.2010.502294Samolov B, Steen B, Seregard S, et al. Delayed inflammation-associated corneal neovascularization in MMP-2-deficient mice. Exp Eye Res. 2005; 80 (2): 159–66. https://doi.org/10.1016/j.exer.2004.08.023Samolov B, Steen B, Seregard S, et al. Delayed inflammation-associated corneal neovascularization in MMP-2-deficient mice. Exp Eye Res. 2005; 80 (2): 159–66. https://doi.org/10.1016/j.exer.2004.08.023Wells JM, Gaggar A, Blalock JE. MMP generated Matrikines. Matrix Biol. 2015; 44–6: 122–9. https://doi.org/10.1016/j.matbio.2015.01.016Wells JM, Gaggar A, Blalock JE. MMP generated Matrikines. Matrix Biol. 2015; 44–6: 122–9. https://doi.org/10.1016/j.matbio.2015.01.016Holmes DI, Zachary I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol. 2005; 6 (2): 209. https://doi.org/10.1186/gb-2005-6-2-209Holmes DI, Zachary I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol. 2005; 6 (2): 209. https://doi.org/10.1186/gb-2005-6-2-209Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol. 2006; 168 (6): 2036–53. doi: 10.2353/ajpath.2006.050588Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol. 2006; 168 (6): 2036–53. doi: 10.2353/ajpath.2006.050588Fu Y-C, Xin Z-M. Inhibited corneal neovascularization in rabbits following corneal alkali burn by double-target interference for VEGF and HIF-1 . Biosci Rep. 2019; 39 (1): BSR20180552. doi: 10.1042/BSR20180552Fu Y-C, Xin Z-M. Inhibited corneal neovascularization in rabbits following corneal alkali burn by double-target interference for VEGF and HIF-1 . Biosci Rep. 2019; 39 (1): BSR20180552. doi: 10.1042/BSR20180552Han K-Y, Dugas-Ford J, Lee H, et al. MMP14 cleavage of VEGFR1 in the cornea leads to a VEGF-trap antiangiogenic effect. Invest Ophthalmol Vis Sci. 2015; 56 (9): 5450–6. https://doi.org/10.1167/iovs.14-16248Han K-Y, Dugas-Ford J, Lee H, et al. MMP14 cleavage of VEGFR1 in the cornea leads to a VEGF-trap antiangiogenic effect. Invest Ophthalmol Vis Sci. 2015; 56 (9): 5450–6. https://doi.org/10.1167/iovs.14-16248Strasly M, Cavallo F, Geuna M, et al. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol. 2001; 166 (6): 3890–9. https://doi.org/10.4049/jimmunol.166.6.3890Strasly M, Cavallo F, Geuna M, et al. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol. 2001; 166 (6): 3890–9. https://doi.org/10.4049/jimmunol.166.6.3890Lai L-J, Xiao X, Wu JH. Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model. J Biomed Sci. 2007; 14 (3): 313–22. https://doi.org/10.1007/s11373-007-9153-7Lai L-J, Xiao X, Wu JH. Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model. J Biomed Sci. 2007; 14 (3): 313–22. https://doi.org/10.1007/s11373-007-9153-7Qi JH, Ebrahem Q, Moore N, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med. 2003; 9 (4): 407–15. https://doi.org/10.1038/nm846Qi JH, Ebrahem Q, Moore N, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med. 2003; 9 (4): 407–15. https://doi.org/10.1038/nm846Hosseini H, Nowroozzadeh MH, Salouti R, et al. Anti-VEGF therapy with bevacizumab for anterior segment eye disease. Cornea. 2012; 31 (3): 322–34. https://doi.org/10.1097/ico.0b013e31822480f9Hosseini H, Nowroozzadeh MH, Salouti R, et al. Anti-VEGF therapy with bevacizumab for anterior segment eye disease. Cornea. 2012; 31 (3): 322–34. https://doi.org/10.1097/ico.0b013e31822480f9Cursiefen C, Colin J, Dana R, et al. Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularization: outcome of an expert roundtable. Br J Ophthalmol. 2012; 96 (1): 3–9. https://doi.org/10.1136/bjo.2011.204701Cursiefen C, Colin J, Dana R, et al. Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularization: outcome of an expert roundtable. Br J Ophthalmol. 2012; 96 (1): 3–9. https://doi.org/10.1136/bjo.2011.204701You IC, Kang IS, Lee SH, Yoon KC. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol. 2009; 87 (6): 653–8. https://doi.org/10.1111/j.1755-3768.2008.01399.xYou IC, Kang IS, Lee SH, Yoon KC. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol. 2009; 87 (6): 653–8. https://doi.org/10.1111/j.1755-3768.2008.01399.xMaddula S, Davis DK, Maddula S, Burrow MK, Ambati BK. Horizons in therapy for corneal angiogenesis. Ophthalmology. 2011; 118 (3): 591–9. https://doi.org/10.1016/j.ophtha.2011.01.041Maddula S, Davis DK, Maddula S, Burrow MK, Ambati BK. Horizons in therapy for corneal angiogenesis. Ophthalmology. 2011; 118 (3): 591–9. https://doi.org/10.1016/j.ophtha.2011.01.041Qazi Y, Wong G, Monson B, Stringham J, Ambati BK. Corneal transparency: genesis, maintenance and dysfunction. Brain Res. Bull. 2010; 81 (2–3): 198–210. https://doi.org/10.1016/j.brainresbull.2009.05.019Qazi Y, Wong G, Monson B, Stringham J, Ambati BK. Corneal transparency: genesis, maintenance and dysfunction. Brain Res. Bull. 2010; 81 (2–3): 198–210. https://doi.org/10.1016/j.brainresbull.2009.05.019Koenig Y, Bock F, Horn F, et al. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2009; 247 (10): 1375–82. https://doi.org/10.1007/s00417-009-1099-1Koenig Y, Bock F, Horn F, et al. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2009; 247 (10): 1375–82. https://doi.org/10.1007/s00417-009-1099-1Bock F, K nig Y, Kruse F, Baier M, Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2008; 246 (2): 281–4. https://doi.org/10.1007/s00417-007-0684-4Bock F, K nig Y, Kruse F, Baier M, Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2008; 246 (2): 281–4. https://doi.org/10.1007/s00417-007-0684-4DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch. Ophthalmol. 2007; 125 (6): 834–6. https://doi.org/10.1001/archopht.125.6.834DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch. Ophthalmol. 2007; 125 (6): 834–6. https://doi.org/10.1001/archopht.125.6.834Jarr n E, Ruiz-Casas D, Mendivil A. Efficacy of bevacizumab against interface neovascularization after deep anterior lamellar keratoplasty. Cornea. 2012; 31 (2): 188–90. https://doi.org/10.1097/ico.0b013e31820ca19eJarr n E, Ruiz-Casas D, Mendivil A. Efficacy of bevacizumab against interface neovascularization after deep anterior lamellar keratoplasty. Cornea. 2012; 31 (2): 188–90. https://doi.org/10.1097/ico.0b013e31820ca19eMaddula S, Davis DK, Maddula S, Burrow MK, Ambati BK; Subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008; 27 (2): 142–7. https://doi.org/10.1097/ico.0b013e318159019fMaddula S, Davis DK, Maddula S, Burrow MK, Ambati BK; Subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008; 27 (2): 142–7. https://doi.org/10.1097/ico.0b013e318159019fKim SW, Ha BJ, Kim EK, Tchah H, Kim TI. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008; 115 (6): e 33–8. https://doi.org/10.1016/j.ophtha.2008.02.013Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008; 115 (6): e 33–8. https://doi.org/10.1016/j.ophtha.2008.02.013Dursun A, Arici MK, Dursun F, et al. Comparison of the effects of bevacizumab and ranibizumab injection on corneal angiogenesis in an alkali burn induced model. Int J Ophthalmol. 2012; 5 (4): 448-51. https://doi.org/10.3980/j.issn.2222-3959.2012.04.08Dursun A, Arici MK, Dursun F, et al. Comparison of the effects of bevacizumab and ranibizumab injection on corneal angiogenesis in an alkali burn induced model. Int J Ophthalmol. 2012; 5 (4): 448-51. https://doi.org/10.3980/j.issn.2222-3959.2012.04.08Sella R, Gal-Or O, Livny E, et al. Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model. Exp Eye Res. 2016; 146: 224-32. https://doi.org/10.1016/j.exer.2016.03.021Sella R, Gal-Or O, Livny E, et al. Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model. Exp Eye Res. 2016; 146: 224-32. https://doi.org/10.1016/j.exer.2016.03.021Totan Y, Aydin E, Ceki O, et al. Effect of caffeic acid phenethyl ester on corneal neovascularization in rats. Curr Eye Res. 2001; 23 (4): 291–7. https://doi.org/10.1076/ceyr.23.4.291.5453Totan Y, Aydin E, Ceki O, et al. Effect of caffeic acid phenethyl ester on corneal neovascularization in rats. Curr Eye Res. 2001; 23 (4): 291–7. https://doi.org/10.1076/ceyr.23.4.291.5453Aydin E, Kivilcim M, Peyman GA, et al. Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline. Cornea 2008 May; 27 (4): 446–53. doi: 10.1097/ICO.0b013e3181605ff9Aydin E, Kivilcim M, Peyman GA, et al. Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline. Cornea 2008 May; 27 (4): 446–53. doi: 10.1097/ICO.0b013e3181605ff9Yoeruek E, Ziemssen F, Henke-Fahle S, et al. T bingen Bevacizumab Study Group. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol. 2008; 86 (3): 322–8. https://doi.org/10.1111/j.1600-0420.2007.01049.xYoeruek E, Ziemssen F, Henke-Fahle S, et al. T bingen Bevacizumab Study Group. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol. 2008; 86 (3): 322–8. https://doi.org/10.1111/j.1600-0420.2007.01049.xYou IC, Kang IS, Lee SH, Yoon KC. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol. 2009; 87 (6): 653–8. https://doi.org/10.1111/j.1755-3768.2008.01399.xYou IC, Kang IS, Lee SH, Yoon KC. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol. 2009; 87 (6): 653–8. https://doi.org/10.1111/j.1755-3768.2008.01399.xHos D, Saban DR, Bock F, et al. Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids. Arch Ophthalmol. 2011; 129 (4): 445–52. https://doi.org/10.1001/archophthalmol.2011.42Hos D, Saban DR, Bock F, et al. Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids. Arch Ophthalmol. 2011; 129 (4): 445–52. https://doi.org/10.1001/archophthalmol.2011.42Nakao S, Hata Y, Miura M, et al. Dexamethasone inhibits interleukin1 -induced corneal neovascularization: role of nuclear factor- B-activated stromal cells in inflammatory angiogenesis. Am J Pathol. 2007; 171 (3): 1058–65. https://doi.org/10.2353/ajpath.2007.070172Nakao S, Hata Y, Miura M, et al. Dexamethasone inhibits interleukin1 -induced corneal neovascularization: role of nuclear factor- B-activated stromal cells in inflammatory angiogenesis. Am J Pathol. 2007; 171 (3): 1058–65. https://doi.org/10.2353/ajpath.2007.070172Hos D, Saban DR, Bock F, et al. Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids. Arch Ophthalmol. 2011; 129 (4): 445–52. https://doi.org/10.1001/archophthalmol.2011.42Hos D, Saban DR, Bock F, et al. Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids. Arch Ophthalmol. 2011; 129 (4): 445–52. https://doi.org/10.1001/archophthalmol.2011.42Utine CA, Stern M, Akpek EK. Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm. 2010; 18 (5): 352–61. https://doi.org/10.3109/09273948.2010.498657Utine CA, Stern M, Akpek EK. Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm. 2010; 18 (5): 352–61. https://doi.org/10.3109/09273948.2010.498657Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009; 50 (10): 4807–13. https://doi.org/10.1167/iovs.08-3148Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009; 50 (10): 4807–13. https://doi.org/10.1167/iovs.08- 3148Chen WL, Lin CT, Lin NT, et al. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci. 2009; 50 (4): 1659–65. https://doi.org/10.1167/iovs.08-1997Chen WL, Lin CT, Lin NT, et al. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci. 2009; 50 (4): 1659–65. https://doi.org/10.1167/iovs.08-1997Hashemian MN, Zare MA, Rahimi F, Mohammadpour M. Deep intrastromal bevacizumab injection for management of corneal stromal vascularization after deep anterior lamellar keratoplasty, a novel technique. Cornea. 2011; 30 (2): 215–8. https://doi.org/10.1097/ico.0b013e3181e291a6Hashemian MN, Zare MA, Rahimi F, Mohammadpour M. Deep intrastromal bevacizumab injection for management of corneal stromal vascularization after deep anterior lamellar keratoplasty, a novel technique. Cornea. 2011; 30 (2): 215–8. https://doi.org/10.1097/ico.0b013e3181e291a6Mohan RR, Tovey JC, Sharma A, Tandon A. Gene therapy in the cornea: 2005–present. Prog. Retin Eye Res. 2012; 31 (1): 43–64. https://doi.org/10.1016/j.preteyeres.2011.09.001Mohan RR, Tovey JC, Sharma A, Tandon A. Gene therapy in the cornea: 2005–present. Prog. Retin Eye Res. 2012; 31 (1): 43–64. https://doi.org/10.1016/j.preteyeres.2011.09.001He Z, Pipparelli A, Manissolle C, et al. Ex vivo gene electrotransfer to the endothelium of organ cultured human corneas. Ophthalmic Res. 2010; 43 (1): 43–55. https://doi.org/10.1159/000246577He Z, Pipparelli A, Manissolle C, et al. Ex vivo gene electrotransfer to the endothelium of organ cultured human corneas. Ophthalmic Res. 2010; 43 (1): 43–55. https://doi.org/10.1159/000246577Cheng HC, Yeh SI, Tsao YP, Kuo PC. Subconjunctival injection of recombinant AAV-angiostatin ameliorates alkali burn induced corneal angiogenesis. Mol Vis. 2007; 13: 2344–52.Cheng HC, Yeh SI, Tsao YP, Kuo PC. Subconjunctival injection of recombinant AAV-angiostatin ameliorates alkali burn induced corneal angiogenesis. Mol Vis. 2007; 13: 2344–52.Zhou SY, Xie ZL, Xiao O, et al. Inhibition of mouse alkali burn induced-corneal neovascularization by recombinant adenovirus encoding human vasohibin-1. Mol Vis. 2010; 16: 1389–98.Zhou SY, Xie ZL, Xiao O, et al. Inhibition of mouse alkali burn induced-corneal neovascularization by recombinant adenovirus encoding human vasohibin-1. Mol Vis. 2010; 16: 1389–98.Cursiefen C, Viaud E, Bock F, et al. Aganirsen Antisense Oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: The I-CAN study. Ophthalmology. 2014; 121 (9): 1683–92. https://doi.org/10.1016/j.ophtha.2014.03.038Cursiefen C, Viaud E, Bock F, et al. Aganirsen Antisense Oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: The I-CAN study. Ophthalmology. 2014; 121 (9): 1683–92. https://doi.org/10.1016/j.ophtha.2014.03.038Rama P, Matuska S, Paganoni G, et al. Limbal stem-cell therapy and longterm corneal regeneration. N Engl J Med. 2010; 363 (2): 147–55. https://doi.org/10.1056/NEJMoa0905955Rama P, Matuska S, Paganoni G, et al. Limbal stem-cell therapy and longterm corneal regeneration. N Engl J Med. 2010; 363 (2): 147–55. https://doi.org/10.1056/NEJMoa0905955

The authors declare that there are no conflicts of interest present.